Clara Suñer

Clara Suñer

Auto-generated profile, based on publicly available information

Clara Suñer

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
CSClara Suñer
Clara Suñer
MUMaria Ubals
Maria Ubals
ETEloy José Tarín-Vicente
Eloy José Tarín-Vicente
AMAdrià Mendoza
Adrià Mendoza
AAAndrea Alemany
Andrea Alemany
OMOriol Mitjà
Oriol Mitjà

7 June 2024 in The Lancet Microbe
Verified
Journal Article
Open access
IMIgor Moraes-Cardoso
Igor Moraes-Cardoso
SBSusana Benet
Susana Benet
JCJulieta Carabelli
Julieta Carabelli
DPDaniel Perez-Zsolt
Daniel Perez-Zsolt
AMAdrià Mendoza
Adrià Mendoza
JGJeremie Guedj
Jeremie Guedj
Since the emergence of the global mpox outbreak in May, 2022, more than 90 000 cases have been diagnosed across 110 countries, disproportionately affecting people with HIV. The durability of mpox-specific immunity is unclear and reinfections have been reported. We aimed to compare mpox immune responses up to 6 months after diagnosis in participants with and without HIV and assess their effect on disease severity and viral clearance dynamics. This study was embedded within a prospective, observational, multicentre cohort study of viral clearance dynamics among people with mpox in Spain (MoViE). We included women and men aged 18 years or older, who had signs of mpox, and reported having symptom onset within the previous 10 days at the moment of mpox diagnosis from three sex clinics of the Barcelona metropolitan area. Samples from skin ulcers were collected weekly to estimate the time to clear monkeypox virus (MPXV) from skin lesions. Blood samples were taken at diagnosis, 29, 91, and 182 days later for immune analysis. This included quantifying IgG and IgA against three mpox antigens by ELISA, evaluating in-vitro neutralisation, and characterising mpox-specific T-cell responses using interferon γ detecting enzyme-linked immunospot (ELISpot) assay and multiparametric flow cytometry. Of the 77 originally enrolled participants, we included 33 participants recruited between July 19, and Oct 6, 2022. Participants without HIV (19 [58%] participants) and participants with HIV (14 [42%] participants) had similar clinical severity and time to MPXV clearance in skin lesions. Participants with HIV had a CD4+ T-cell count median of 777 cells per μL (IQR 484-1533), and 11 (78%) of 14 were virally suppressed on antiretroviral therapy. Nine (27%) of 33 participants were age 49 years or older. 15 (45%) of 33 participants were originally from Spain, and all participants were men. Early humoral responses, particularly concentrations and breadth of IgG and IgA, were associated with milder disease and faster viral clearance. Orthopoxvirus-specific T cells count was also positively correlated with MPXV clearance. Antibody titres declined more rapidly in participants with HIV, but T-cell responses against MPXV were sustained up to day 182 after diagnosis, regardless of HIV status. Higher breadth and magnitude of B-cell and T-cell responses are important in facilitating local viral clearance, limiting mpox dissemination, and reducing disease severity in individuals with preserved immune system. Antibodies appear to contribute to early viral control and T-cell responses are sustained over time, which might contribute to milder presentations during reinfection. Fundació Lluita contra les Infeccions, IrsiCaixa, and Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación e Universidades.

28 June 2021 in Nature Aging
Verified
Journal Article
Closed access
PDF file
CSClara Suñer
Clara Suñer
DODan Ouchi
Dan Ouchi
MMMiquel Mas
Miquel Mas
RARosa Lopez Alarcon
Rosa Lopez Alarcon
MMMireia Massot Mesquida
Mireia Massot Mesquida
OMOriol Mitjà
Oriol Mitjà

20 April 2022 in eLife
Verified
Journal Article
Open access
CSClara Suñer
Clara Suñer
ASAnnarita Sibilio
Annarita Sibilio
JMJudit Martín
Judit Martín
CCChiara Lara Castellazzi
Chiara Lara Castellazzi
OROscar Reina
Oscar Reina
RMRaúl Méndez
Raúl Méndez
Chronic inflammation is a major cause of disease. Inflammation resolution is in part directed by the differential stability of mRNAs encoding pro-inflammatory and anti-inflammatory factors. In particular, tristetraprolin (TTP)-directed mRNA deadenylation destabilizes AU-rich element (ARE)-containing mRNAs. However, this mechanism alone cannot explain the variety of mRNA expression kinetics that are required to uncouple degradation of pro-inflammatory mRNAs from the sustained expression of anti-inflammatory mRNAs. Here, we show that the RNA-binding protein CPEB4 acts in an opposing manner to TTP in macrophages: it helps to stabilize anti-inflammatory transcripts harboring cytoplasmic polyadenylation elements (CPEs) and AREs in their 3′-UTRs, and it is required for the resolution of the lipopolysaccharide (LPS)-triggered inflammatory response. Coordination of CPEB4 and TTP activities is sequentially regulated through MAPK signaling. Accordingly, CPEB4 depletion in macrophages impairs inflammation resolution in an LPS-induced sepsis model. We propose that the counterbalancing actions of CPEB4 and TTP, as well as the distribution of CPEs and AREs in their target mRNAs, define transcript-specific decay patterns required for inflammation resolution. Thus, these two opposing mechanisms provide a fine-tuning control of inflammatory transcript destabilization while maintaining the expression of the negative feedback loops required for efficient inflammation resolution; disruption of this balance can lead to disease.

15 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
RPRosa Pascual
Rosa Pascual
JMJudit Martín
Judit Martín
FSFernando Salvador
Fernando Salvador
OROscar Reina
Oscar Reina
VCVeronica Chanes
Veronica Chanes
RMRaúl Méndez
Raúl Méndez
The RNA binding protein CPEB2 defines a new posttranscriptional layer in the hormone-driven gene-expression reprogramming.

1 January 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MIMarta Isasa
Marta Isasa
CSClara Suñer
Clara Suñer
MDMiguel Díaz
Miguel Díaz
PPPilar Puig-Sàrries
Pilar Puig-Sàrries
AZAlice Zuin
Alice Zuin
Bernat CrosasBernat Crosas
Bernat Crosas
Despite multiple evidence of the involvement of the proteasome-ubiquitin signaling system in temperature stress response, the dynamics of the ubiquitylome during cold response has not yet been studied. Here, we have compared quantitative ubiquitylomes from a strain deficient in proteasome substrate recruitment and a reference strain during cold response. We have observed that a large group of proteins showing increased ubiquitylation in the proteasome mutant at low temperature is comprised by Reverses SPT-Phenotype 5 (RSP5)-regulated plasma membrane proteins. Analysis of internalization and degradation of plasma membrane proteins at low temperature showed that the proteasome becomes determinant for this process, whereas, at 30°C, the proteasome is dispensable. Moreover, our observations indicate that proteasomes have increased capacity to interact with lysine 63-polyubiquitylated proteins during low temperature, in vivo. These unanticipated observations indicate that, during cold response, there is a proteolytic cellular reprogramming in which the proteasome acquires a role in the endocytic-vacuolar pathway.